| Autor: |
Wypij JM; Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Hazelwood Drive, Urbana, IL 61802, USA., Pondenis HC |
| Jazyk: |
angličtina |
| Zdroj: |
Veterinary medicine international [Vet Med Int] 2013; Vol. 2013, pp. 786162. Date of Electronic Publication: 2013 Apr 28. |
| DOI: |
10.1155/2013/786162 |
| Abstrakt: |
Background. L-asparaginase is effective in treating canine and feline lymphoma, however chemotherapy poses a significant financial cost to veterinary clients, limiting therapy for many pets. Single dose vials result in significant drug wastage, and drug shortages limit consistent availability for pets. Hypothesis. E. coli-derived asparaginase retains enzymatic and antineoplastic activity in canine and feline lymphoma cells after cold storage. Methods. E. coli-derived asparaginase was cold-stored: refrigeration (7-14 days) and freezing (14 days-six months, one to three freeze/thaw cycles). Enzymatic activity of asparaginase was measured via a modified asparagine assay. Effects of cold-stored asparaginase on cell proliferation and cytotoxicity were measured in feline (MYA-1, F1B) and canine (17-71, OSW) lymphoma cells. Results. Cold-stored E. coli-derived asparaginase retains antineoplastic activity in all four cell lines tested. Cold-stored E. coli-derived L-asparaginase depletes asparagine and retains enzymatic activity. Duration of refrigeration, duration of freezing, and number of freeze-thaw cycles have minimal effect on asparaginase enzyme activity. Conclusions and Clinical Importance. This study establishes a scientific basis for long-term cold storage of reconstituted E. coli-derived asparaginase that may result in better utilization of limited drug resources and improve financial feasibility of E. coli-derived asparaginase as a therapeutic option for pets with lymphoma. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
